Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-Label, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 in Pediatric Subjects With Congenital Adrenal Hyperplasia

NCT04045145 is registered in ClinicalTrials.gov with Neurocrine Biosciences as lead sponsor.

NCT NCT04045145
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04045145 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-Label, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 in Pediatric Subjects With Congenital Adrenal Hyperplasia
Lead sponsor
Neurocrine Biosciences
Phase
Phase 2
Overall status
Completed
Start date
December 12, 2019
Completion date
July 2, 2021
Enrollment
8 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

cah - congenital adrenal hyperplasia